Accounting for over 30% of all proteins in the human genome, membrane proteins take an important part in materials transportation, signal transduction, intercellular recognition ligand-receptor binding, cell adhesion, etc., over 60% of which currently prove to be drug targets. Integrated with multiple cutting-edge technologies, the novel platform, Magic™ launched by Creative Biolabs enables comprehensive services for membrane… Read more »
Posts Categorized: Biotechnology
Creative Biolabs Updated Antibodies Conducive to Immunology Research
Having been busy attending online conferences and holding virtual webinars for the past 2 years, Creative Biolabs has proudly announced this year’s back to in-person events, which will be exhibiting at PEGS Boston and BIO International Convention in the not far future. Kicking off the Spring of 2022 is not only the announcement of in-person… Read more »
Creative Biolabs Announces Sponsorship and Exhibition at PEGS Boston 2022
The past two years have witnessed the COVID-19 shutdown and rising digital meetings as well as the breakthroughs in biotechnology such as mRNA vaccine. Scientists worldwide never stop their exploration in life science, and neither does Creative Biolabs. As the conference and exhibition back to in person, Creative Biolabs is delighted to rejoin biotech partnering… Read more »
Artemis DNA Announces Global Expansion, Begins Offering Genetic Testing and Early Detection of Cancer Technology to Vietnam
Artemis DNA, Inc. (“Artemis DNA” or the “company”), a full-service, accredited, high complexity clinical diagnostic laboratory company providing proprietary Next Generation Sequencing (NGS) genetic and diagnostic testing that enables “personalized” medicine through early disease detection, proudly announced today that they will be opening their first international location at 88 Nguyen Du, Ben Nghe, Quan 1 in Ho Chi… Read more »
DelNova to Advance ReViVox™, A Groundbreaking Rescue Drug to Reverse Botulinum Toxin Neuromodulator Complications
DelNova, a biopharmaceutical company targeting unmet medical needs, by developing clinically validated molecules linked to advances in drug delivery, announced today that the company is making substantive progress in developing the first ever product to reverse complications arising from administration of botulinum toxin neuromodulators, such as BOTOX®, Dysport®, XEOMIN®, and Jeuveau®. According to the syndicated… Read more »
